Citius Pharmaceuticals is trading 10.25% down at $0.49 in pre-market, with no specific catalyst established for the decline. - Citius Oncology announced positive LYMPHIR quality-of-life results from pivotal Study 302, presented at the EORTC-CLTG 2026 meeting, describing sustained improvements among responders. - Healthcare sector strength points in the opposite direction.